Article

Homologous and heterologous antibody responses to a one-year booster dose of an MF59 (R) Adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

University of Tampere Medical School
Human Vaccines & Immunotherapeutics (Impact Factor: 3.64). 07/2012; 8(7):921-8. DOI: 10.4161/hv.20248
Source: PubMed

ABSTRACT Background: Primary immunization with two doses of MF59 (®) -adjuvanted A/H5N1 influenza vaccine has been shown to be highly immunogenic and well tolerated in children and adolescents. Assessment of long-term antibody persistence after priming, and the effects of a one-year booster dose in children and adolescents was needed. Objectives This study assessed homologous and heterologous antibody responses to a one-year booster dose of MF59-adjuvanted A/H5N1 influenza vaccine in previously primed children. Subjects and methods: Twelve months after primary vaccination, toddlers, children and adolescents received a single booster dose of the same A/H5N1 vaccine. Paired sera were collected before and three weeks after booster vaccination. Homologous antibody responses against the A/Vietnam/1194/2004 vaccine strain were measured by hemagglutination inhibition (HI), single radial hemolysis (SRH) and microneutralization (MN) assays. Heterologous antibody responses against A/Indonesia/5/2005 and A/Anhui/1/2005 strains were assessed by MN assay only. Results: Twelve months after primary vaccination, persistent, homologous, seroprotective HI antibody titers (≥ 40) were observed in 46%, 26% and 30% of toddlers, children and adolescents; following booster vaccination, seroprotection rates increased to 99%, 98% and 91%, respectively. All toddlers and children, and 99% of adolescents achieved MN antibody titers ≥ 40. Cross-reactive A/H5N1 antibodies were detected in 94-98% of subjects after booster vaccination. Conclusions Two priming doses of MF59-adjuvanted A/H5N1 vaccine resulted in homologous and heterologous antibody responses which persisted for up to one year after immunization. A one-year booster dose was highly immunogenic, generating high homologous and cross-reactive A/H5N1 antibody titers.

0 Followers
 · 
104 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Studies on candidate pandemic vaccines against avian influenza virus have focussed on H5N1, but viruses of other subtypes, such as A/H9N2, are also considered to have pandemic potential. We investigated the safety and immunogenicity of two immunizations with one of five different antigen doses (ranging from 3.75 to 45 μg hemagglutinin antigen) of a non-adjuvanted, whole-virus G9-lineage H9N2 vaccine in healthy adults aged 18-49 years. Antibody responses were measured by hemagglutination inhibition (HI), microneutralization (MN) and single radial hemolysis (SRH) assays. To investigate a hypothesis that previous exposure to H2N2 viruses in subjects born in or before 1968 might prime for more robust antibody responses to H9N2 vaccination, a post-hoc age-stratified analysis of antibody responses was done. Both vaccinations in all dose groups were safe and well-tolerated. No vaccine-related serious adverse events were reported, and the majority of adverse reactions were rated as mild. Injection site reaction rates were lower in the 3.75 μg and 7.5 μg dose groups compared to the higher dose groups; systemic reaction rates were similar across all dose groups. Seroprotection rates among the different dose groups 21 days after the second immunization ranged from 52.8% to 88.9% measured by HI assay, from 88.7% to 98.1% or 82.7% to 96.2% measured by MN assay (MN titer cut-off 1:40 and 1:80, respectively), and from 94.2% to 100% measured by SRH assay. Higher antibody responses were not induced in subjects born in or before 1968. These data indicate that a non-adjuvanted, whole-virus H9N2 vaccine is well-tolerated and immunogenic in healthy adults.
    Clinical and vaccine Immunology: CVI 10/2014; DOI:10.1128/CVI.00275-14 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The threat of an outbreak of avian-origin influenza H7N9 and the devastating consequences that a pandemic could have on global population health and economies has mobilized programs of constant surveillance and the implementation of preemptive plans. Central to these plans is the production of prepandemic vaccines that can be rapidly deployed to minimize disease severity and deaths resulting from such an occurrence. In this article, we review current H7N9 vaccine strategies in place and the available technologies and options that can help accelerate vaccine production and increase dose-sparing capabilities to provide enough vaccines to cover the population. We also present possible means of reducing disease impact during the critical period after an outbreak occurs before a strain matched vaccine becomes available and consider the use of existing stockpiles and seed strains of phylogenetically related subtypes, alternate vaccination regimes and vaccine forms that induce cross-reactive immunity.
    Expert Review of Vaccines 07/2014; 13(11). DOI:10.1586/14760584.2014.938641 · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inactivated influenza vaccines are produced every year to fight against the seasonal epidemics of influenza. Despite the nonoptimal coverage, even in subjects at risk like the elderly, pregnant women, etc., these vaccines significantly reduce the burden of mortality and morbidity linked to the influenza infection. Importantly, these vaccines have also contributed to reduce the impact of the last pandemics. Nevertheless, the performance of these vaccines can be improved mainly in those age groups, like children and the elderly, in which their efficacy is suboptimal. The use of adjuvants has proven effective to this scope. Oil-in-water adjuvants like MF59 and AS03 have been licensed and widely used, and shown efficacious in preventing influenza infection in the last pandemic. MF59-adjuvanted inactivated vaccine was more efficacious than non-adjuvanted vaccine in preventing influenza infection in young children and in reducing hospitalization due to the influenza infection in the elderly. Other adjuvants are now at different stages of development and some are being tested in clinical trials. The perspective remains to improve the way inactivated vaccines are prepared and to accelerate their availability, mainly in the case of influenza pandemics, and to enhance their efficacy/effectiveness for a more successful impact at the public health level.
    Current topics in microbiology and immunology 07/2014; DOI:10.1007/82_2014_406 · 3.47 Impact Factor